Toxicity of JAK inhibition for ABC DLBCL cell lines and synergism with NF-κB pathway inhibition. (A) ABC DLBCL (OCI-Ly3, OCI-Ly10, HBL1, and SUDHL2) and GCB DLBCL (OCI-Ly7, HT, HS602) were treated with 0 to 50 μmol/L JAK inhibitor for 2 days and assigned for viability by MTT assays. The cell numbers at each drug dose are expressed as the percentage of cell numbers obtained with untreated cells cultured in parallel. (B) OCI-Ly10 cells were treated with JAK inhibitor (0-10 μmol/L) or U0126 (0-12.5 μmol/L) for 4 hours. Cell lysate was made for the measurement of phospho-STAT3 (Tyr705). (C) Gene-expression patterns of lymphoma cell line OCI-Ly10 treated with 5 μmol/L JAK inhibitor for 3 and 6 hours. (D) JAK inhibitor treatment diminishes IL-6 and IL-10 secretion. OCI-Ly3 and OCI-Ly10 cells were washed before adding JAK inhibitor. Shown are relative cytokine units from ELISAs for IL-6 (OCI-Ly3) and IL-10 (OCI-Ly10) using supernatants of cells that were washed with fresh media immediately before addition of the JAK inhibitor. (E) OCI-Ly3, OCI-Ly10, and HBL1 cells were treated with both JAK inhibitor and MLN120B for 3 days and assigned for viability by MTT assays. The cell numbers at each drug dose are expressed as the percentage of cell numbers obtained with untreated cells cultured in parallel.